With eyes on an IPF fran­chise, Gala­pa­gos push­es sec­ond can­di­date in­to a dose-find­ing study

While the proof-of-con­cept re­sults for Gala­pa­gos’ sec­ond id­io­path­ic pul­monary fi­bro­sis can­di­date didn’t turn up quite as much ex­cite­ment as its lead can­di­date, the Bel­gian biotech says it’s enough to push for­ward with a dose-find­ing study.

The Phase II study as­sessed GLPG1205 in 68 IPF pa­tients over 26 weeks. Vol­un­teers were al­lowed to con­tin­ue their stan­dard of care, in­clud­ing nintedanib and pir­fenidone. While the ear­ly study “was not pow­ered to show sta­tis­ti­cal sig­nif­i­cance,” ac­cord­ing to the com­pa­ny, those in the treat­ment arm showed a small­er forced vi­tal ca­pac­i­ty (FVC) de­cline from base­line than those on a place­bo — 34 mL, com­pared to 76 mL in the place­bo arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER